Ashley Holder, M.D., FACS
Department of Surgical Oncology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | Baylor College of Medicine, Houston, Texas, US, MD (with Honors, Howard Hughes Medical Institute Medical Student Research Fellowship in Genetics) |
| 2003 | Davidson College, Davidson, North Carolina, US, Biology, BS |
Postgraduate Training
| 2015-2017 | Fellowship, Complex General Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2013 | T32 Postdoctoral Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2008-2015 | Internship and Residency, General Surgery, Washington University/Barnes-Jewish Consortium, St. Louis, Missouri |
| null-2017 | Rice Education in Management for Physician Trainees Certificate Program, Rice University, Houston, Texas |
Licenses & Certifications
| 2024 | Mississippi State Board of Medical Licensure |
| 2024 | Georgia Composite Medical Board |
| 2024 | Oklahoma State Board of Medical Licensure |
| 2024 | Florida Board of Medicine |
| 2024 | Washington State Department of Health |
| 2024 | Arizona Board of Medical Examiners |
| 2024 | Tennessee Board of Medical Examiners |
| 2024 | Louisiana State Board of Medical Examiners |
| 2018 | American Board of Surgery, Complex General Surgical Oncology |
| 2016 | American Board of Surgery, General Surgery |
| 2016 | Physician License, Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2023
Assistant Professor, Department of Surgery, Institute for Academic Medicine, Houston, TX, 2017 - 2020
Assistant Professor, Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 2017 - 2020
Assistant Professor, Department of Surgery, Weill Cornell Medical College, New York, NY, 2017 - 2020
Adjunct Assistant Professor, Department of Surgery, Texas A&M University College of Medicine, Bryan, TX, 2017 - 2020
Administrative Appointments/Responsibilities
NIH/NCI T32 Associate Program Director, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Section Chief, Surgical Oncology, Birmingham VA Medical Center, Birmingham, AL, 2022 - 2023
Disease Site Leader for Skin and Soft Tissue Malignancies, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, 2021 - 2023
Quality Review Representative for the, Division of Surgical Oncology, O'Neal Comprehensive Cancer Center Tumor Registry, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2021
Chair, Melanoma and Sarcoma Disease Oriented Group, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, 2019 - 2020
Walter F. Ballinger Administrative Chief Resident, Department of General Surgery, Washington University in St. Louis, St. Louis, MO, 2014 - 2015
Other Professional Positions
Member, American Joint Committee on Cancer (AJCC) Neoadjuvant Ad Hoc Working Group, Chicago, IL, 2023 - Present
Member, American Joint Committee on Cancer (AJCC) Communications Committee, Chicago, IL, 2023 - Present
Member, O’Neal Comprehensive Cancer Center Cancer Committee, University of Alabama at Birmingham, Birmingham, AL, 2022 - 2023
Member, Clinical Events Committee, Physician sponsored investigational device exemption study for custom aortic endografts to treat thoracoabdominal aneurysms, University of Alabama at Birmingham, Birmingham, AL, 2021 - 2023
Surgery Department Representative, UAB Cancer Hospital Planning Oversight Committee, University of Alabama at Birmingham, Birmingham, AL, 2021 - 2023
Member, Center for Clinical and Translational Science (CCTS), University of Alabama at Birmingham, Birmingham, AL, 2021 - 2023
Chair, Melanoma/Sarcoma Working Group, O’Neal Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, 2021 - 2021
Young Fellows Representative, Executive Council, Alabama Chapter of the American College of Surgeons, Birmingham, AL, 2021 - 2022
Coordinator, Surgical Oncology Staging Conference, Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2023
Surgical Oncology Acting Internship, Director, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2023
Moderator and Coordinator, Sarcoma Management Conference, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2023
Member, Search Committee for Surgical Director of Lung Transplant, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2021
Grand Rounds Co-Leader, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 2020 - 2022
Review Editor, TVEC Injectable Oncolytic Virus Clinical Policy, University of Alabama at Birmingham, Birmingham, AL, 2020 - Present
UAB/O’Neal Cancer Center Representative, Melanoma Panel, National Cancer Consortium Network, Plymouth Meeting, PA, 2020 - 2023
UAB/O’Neal Cancer Center Representative, Sarcoma Panel, National Cancer Consortium Network, Plymouth Meeting, PA, 2020 - 2023
UAB/O’Neal Cancer Center Representative, Non-melanoma Skin Cancer Panel, National Cancer Consortium Network, Plymouth Meeting, PA, 2020 - 2021
Member, ECOG-ACRIN HIPEC Working Group, Philadelphia, PA, 2019 - 2023
Moderator, General Surgery Morbidity and Mortality Conference, Houston Methodist Hospital, Houston, TX, 2018 - 2019
Assistant Member, Houston Methodist Research Institute, Houston, TX, 2017 - 2020
Member, Clinical Nutrition Subcommittee, Houston Methodist Hospital, Houston, TX, 2017 - 2020
Clinical Specialist, The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX, 2015 - 2017
Editorial Activities
Early Career Editorial Board Member, Physiological Reviews, 2022 - Present
Review Editor, Frontiers in Oncology, Skin Cancer Section, 2020 - Present
Honors & Awards
| 2024 | Women in Cancer Immunotherapy Leadership Institute, Society for Immunotherapy of Cancer |
| 2022 | John Kirklin Award for Engagement in Academic Surgery, Department of Surgery, University of Alabama at Birmingham |
| 2022 | Patient Experience Leader, University of Alabama at Birmingham, Office of Patient Experience and Engagement |
| 2021 | Participant, AAMC Virtual Leadership Development Seminar for Women Faculty in Medicine and Science |
| 2021 | CSW Sees You Award, University of Alabama at Birmingham Commission on the Status of Women |
| 2021 | Exceptional care provider (98% and above), University of Alabama at Birmingham, Office of Patient Experience and Engagement |
| 2021 | Melanoma Research Foundation Career Development Award, (Returned given overlap with ACS Clowes Award) |
| 2019 | Best in Category for Basic Science, Travel Award, Houston Methodist Cancer Center Symposium |
| 2017 | Daniel Benedict Gazan Fellowship in Sarcoma Research, The University of Texas MD Anderson Cancer Center |
| 2017 | Rice Education in Management for Physician Trainees, Department of Surgical Oncology Scholarship The University of Texas MD Anderson Cancer Center |
| 2014 | ACS Jameson L. Chassin, MD, FACS Award for Professionalism in General Surgery, Top Ten Finalist |
| 2011 | NIH Ruth L. Kirschstein National Research Service Award T32 Postdoctoral Fellowship, The University of Texas MD Anderson Cancer Center |
| 2009 - 2010 | Medical Student Teaching Award, Department of General Surgery, Washington University in St. Louis |
| 2007 | Member, Alpha Omega Alpha |
| 2006 | Student Delegate, International Summit, Academy of Achievement |
| 2004 | Student Representative, Texas Medical Association Foundation, Board of Trustees Student Delegate, International Summit, Academy of Achievement |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2023. Dissecting Melanoma Lymph Node Metastases. Conference. Dissecting Melanoma Lymph Node Metastases, US.
National Presentations
- 2024. Social Vulnerability Index Correlates with Gut Microbiome Diversity and Predicts Survival in Advanced Melanoma and Sarcoma Patients Treated with Immune Checkpoint Blockade. Conference. Social Vulnerability Index Correlates with Gut Microbiome Diversity and Predicts Survival in Advanced Melanoma and Sarcoma Patients Treated with Immune Checkpoint Blockade. Atlanta, GA, US.
- 2024. Adrenal Insufficiency in the Immunotherapy Era – A Quality Improvement Project to Identify Those at Risk Prior to Melanoma Surgery. Conference. Adrenal Insufficiency in the Immunotherapy Era – A Quality Improvement Project to Identify Those at Risk Prior to Melanoma Surgery. Atlanta, GA, US.
- 2023. Development of an In Vivo Melanoma Model of Immune Cell Trafficking from Primary Tumor to Tumor-Draining Lymph Nodes. Conference. Development of an In Vivo Melanoma Model of Immune Cell Trafficking from Primary Tumor to Tumor-Draining Lymph Nodes. Philadelphia, PA, US.
- 2023. Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Ultrasound. Conference. Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Ultrasound. Boston, MA, US.
- 2023. What to take from training to your first job. Conference. What to take from training to your first job, US.
- 2023. Role of Microbiome and Immune Response in Melanoma. Conference. Role of Microbiome and Immune Response in Melanoma. Houston, TX, US.
- 2023. Is It Time for Synoptic Reporting in Melanoma Nodal Surveillance Ultrasonography?. Conference. Is It Time for Synoptic Reporting in Melanoma Nodal Surveillance Ultrasonography?. Boston, MA, US.
- 2023. Macrophages and melanoma metastases in the draining lymph node basin. Conference. Macrophages and melanoma metastases in the draining lymph node basin, US.
- 2022. Integrating Imaging and Tissue-Based Analysis to Unravel Treatment Response and Resistance Mechanisms in Melanoma. Conference. Integrating Imaging and Tissue-Based Analysis to Unravel Treatment Response and Resistance Mechanisms in Melanoma. Boston, MA, US.
- 2022. Patterns of Care and Data Quality in a National Registry of Black and White Patients with Merkel Cell Carcinoma. Conference. Patterns of Care and Data Quality in a National Registry of Black and White Patients with Merkel Cell Carcinoma. San Diego, CA, US.
- 2022. Medical Student Program: Mock Interview Practice Session. Conference. Medical Student Program: Mock Interview Practice Session. San Diego, CA, US.
- 2022. Non-Cutaneous Melanoma. Conference. Non-Cutaneous Melanoma. Denver, CO, US.
- 2022. Non-Cutaneous Melanoma. Conference. Non-Cutaneous Melanoma. Fort Lauderdale, GA, US.
- 2022. Effect of Macrophage Migration to Tumor-Draining Lymph Nodes in Melanoma. Conference. Effect of Macrophage Migration to Tumor-Draining Lymph Nodes in Melanoma. Birmingham, AL, US.
- 2022. Modulation of the Immune Microenvironment by Tumor-derived Macrophages in a Murine Model of B16F10 Melanoma. Conference. Modulation of the Immune Microenvironment by Tumor-derived Macrophages in a Murine Model of B16F10 Melanoma. Orlando, FL, US.
- 2021. Melanoma: What Happens After Referral. Conference. Melanoma: What Happens After Referral, US.
- 2021. Ranking NIH Funding of Surgical Departments Based Upon a Modified Index. Conference. Ranking NIH Funding of Surgical Departments Based Upon a Modified Index. Chicago, IL, US.
- 2021. Current Management of a Positive Sentinel Node Biopsy for Cutaneous Melanoma. Conference. Current Management of a Positive Sentinel Node Biopsy for Cutaneous Melanoma, US.
- 2021. Merkel Cell Carcinoma: A Rare Cancer. Conference. Merkel Cell Carcinoma: A Rare Cancer. Miramar Beach, FL, US.
- 2021. Virtual or In-Person? Grand Rounds in the Era of COVID-19. Conference. Virtual or In-Person? Grand Rounds in the Era of COVID-19. Virtual, US.
- 2020. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Conference. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Orlando, FL, US.
- 2019. Surgical Management of Skin & Soft Tissue Tumors. Conference. Surgical Management of Skin & Soft Tissue Tumors. Houston, TX, US.
- 2019. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Conference. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Houston, TX, US.
- 2017. Identifying Patients Most Likely to Benefit from Salvage Surgery for Recurrent or Metastatic Uterine Leiomyosarcoma. Conference. Identifying Patients Most Likely to Benefit from Salvage Surgery for Recurrent or Metastatic Uterine Leiomyosarcoma. Seattle, WA, US.
- 2016. Hereditary Colorectal Cancer. Conference. Hereditary Colorectal Cancer. Virtual, US.
- 2016. Completion of Follow-up After Abnormal Screening Test for Lynch Syndrome: A Framework for multi-level cancer care delivery. Conference. Completion of Follow-up After Abnormal Screening Test for Lynch Syndrome: A Framework for multi-level cancer care delivery. San Diego, CA, US.
- 2014. Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment. Conference. Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment. San Diego, CA, US.
- 2013. Epithelial to Mesenchymal Transition (EMT) and Rapamycin Sensitivity in Cancer Cell Lines. Conference. Epithelial to Mesenchymal Transition (EMT) and Rapamycin Sensitivity in Cancer Cell Lines. Washington, DC, US.
- 2012. Increased Stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Conference. Increased Stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Chicago, IL, US.
- 2008. High resolution array comparative genome hybridization reveals de novo and rare inherited changes in patients with congenital diaphragmatic hernia. Conference. High resolution array comparative genome hybridization reveals de novo and rare inherited changes in patients with congenital diaphragmatic hernia. Philadelphia, PA, US.
- 2008. Identifying Genes for Congenital Diaphragmatic Hernia. Conference. Identifying Genes for Congenital Diaphragmatic Hernia. Washington, DC, US.
- 2006. Haploinsufficiency of COUP-TFII in Congenital Diaphragmatic Hernia. Conference. Haploinsufficiency of COUP-TFII in Congenital Diaphragmatic Hernia. San Francisco, CA, US.
- 2006. Genetic etiologies for congenital diaphragmatic hernia. Conference. Genetic etiologies for congenital diaphragmatic hernia. Chevy Chase, MD, US.
- 2006. Genetic etiologies for congenital diaphragmatic hernia. Conference. Genetic etiologies for congenital diaphragmatic hernia. Houston, TX, US.
- 2004. Effects of diuretics and papaverine during hand-assisted, laparoscopic, donor nephrectomy. Conference. Effects of diuretics and papaverine during hand-assisted, laparoscopic, donor nephrectomy. New Orleans, LA, US.
International Presentations
- 2021. Novel 3-D Modeling Process to Determine Treatment Surface Area (SA) and Volume for Chemotherapeutic Dosing in HIPEC. Conference. Novel 3-D Modeling Process to Determine Treatment Surface Area (SA) and Volume for Chemotherapeutic Dosing in HIPEC. Virtual, US.
- 2020. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Conference. Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC. Virtual, US.
- 2020. Innovative Technique Incorporating Intraoperative Measurements of Lymphatic Transport Predicts Metastatic Potential in Melanoma. Conference. Innovative Technique Incorporating Intraoperative Measurements of Lymphatic Transport Predicts Metastatic Potential in Melanoma. Virtual, US.
- 2016. Operating rooms and equipment used for HIPEC are at risk for chemotherapy contamination. Conference. Operating rooms and equipment used for HIPEC are at risk for chemotherapy contamination. Washington, US.
- 2016. Decision for non-completion of followup among patients with abnormal screening test for hereditary colorectal cancer syndrome. Conference. Decision for non-completion of followup among patients with abnormal screening test for hereditary colorectal cancer syndrome. Vancouver, CA.
- 2007. Genome-Wide Oligonucleotide-Based Array Comparative Genome Hybridization Analysis of Non-Isolated Congenital Diaphragmatic Hernia. Conference. Genome-Wide Oligonucleotide-Based Array Comparative Genome Hybridization Analysis of Non-Isolated Congenital Diaphragmatic Hernia. Toronto, CA.
- 2006. Genetic etiologies for congenital diaphragmatic hernia. Conference. Genetic etiologies for congenital diaphragmatic hernia. Brisbane, AT.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | Targeting the gut microbiome to inhibit melanoma lymph node metastases |
| Funding Source: | NIH/NCI Multi-PI R01 |
| Role: | Principal Investigator-MDACC |
| Date: | 2023 - 2028 |
| Title: | Gut Microbiome in Melanoma Lymph Node Metastasis |
| Funding Source: | UT MD Anderson Cancer Center Start-up Funds |
| Role: | Principal Investigator-MDACC |
| Date: | 2022 - 2026 |
| Title: | Macrophage Regulation of the Tumor Microenvironment in Metastatic Melanoma |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | Melanoma Academy Scholar Award |
| Date: | 2022 - 2027 |
| Title: | Macrophage Regulation of the Tumor Microenvironment in Metastatic Melanoma |
| Funding Source: | American College of Surgeons |
| Role: | PI |
| ID: | George HA Clowes Award |
| Date: | 2021 - 2022 |
| Title: | Eliminating the Exit Strategy for Macrophages in Cutaneous Melanoma |
| Funding Source: | Faculty Development Grant Program |
| Role: | PI |
| ID: | UAB |
| Date: | 2019 - 2020 |
| Title: | Gold Nanorod-Mediated Hyperthermia to Improve Chemotherapeutic Efficacy in HIPEC |
| Funding Source: | Houston Methodist Translational Research Initiative |
| Role: | PI |
| Date: | 2019 - 2019 |
| Title: | The Impact of Lymphatic Transport Kinetics on Metastatic Potential in Melanoma |
| Funding Source: | Houston Methodist SPG Performance Grant |
| Role: | PI |
| Date: | 2019 - 2019 |
| Title: | Neoadjuvant Immunotherapy for Patients with Cutaneous Melanoma and Occult Nodal Metastases |
| Funding Source: | Houston Methodist SPG Performance Grant |
| Role: | Co-I |
| Date: | 2018 - 2020 |
| Title: | Nanoparticle-Mediated Hyperthermia to Improve Chemotherapeutic Efficacy in HIPEC for Gastric Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Neoadjuvant Checkpoint Inhibition for High-Risk Nonmetastatic Resectable Cutaneous Melanoma |
| Funding Source: | Weill Cornell Medicine/Houston Methodist Mentored Clinical Research Training Program |
| Role: | PI |
| Date: | 2011 - 2013 |
| Title: | Targeting Rapamycin Resistance in Breast Cancer |
| Funding Source: | NIH T32 Fellowship |
| Role: | Mentor |
| Date: | 2005 - 2006 |
| Title: | Genetic Etiologies of Congenital Diaphragmatic Hernia |
| Funding Source: | HHMI Fellowship |
| Role: | Mentor |
Selected Publications
Peer-Reviewed Articles
- Fields BC, Jain AJ, Prieto VG, Frink SJ, Holder AM. Pigmented Villonodular Synovitis: A Metastatic Melanoma Imitator. Am J Dermatopathol 46(9):e77-e78, 2024. e-Pub 2024. PMID: 39008502.
- Montgomery KB, Holder AM, Broman KK. ASO Author Reflections: Synoptic Reporting for Melanoma Nodal Surveillance Ultrasonography. Ann Surg Oncol 31(12):8253-8254, 2024. e-Pub 2024. PMID: 39012465.
- Montgomery KB, Duncan ZN, Holder AM, Burgan CM, Galgano SJ, Broman KK. Interdisciplinary Implementation of a Synoptic Reporting Template for Melanoma Nodal Surveillance Ultrasound. Ann Surg Oncol 31(12):8222-8229, 2024. e-Pub 2024. PMID: 38954095.
- Fields BC, Traweek RS, Nassif E, Witt R, Keung E, Chelvanambi M, Damania AV, Somaiah N, Wargo JA, Roland CL, Holder AM. Social Vulnerability Index Correlates with Gut Microbiome Diversity and Predicts Survival in Advanced Melanoma and Sarcoma Patients Treated with Immune Checkpoint Blockade, 2024. e-Pub 2024.
- Holder AM, Wargo JA, Ross MI. Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma. Ann Surg Oncol 30(12):6953-6957, 2023. e-Pub 2023. PMID: 37661225.
- Montgomery KB, Holder AM, Burgan CM, Galgano SJ, Broman KK. Is it Time for Synoptic Reporting in Melanoma Nodal Surveillance Ultrasonography?. Ann Surg Oncol 30(9):5327-5328, 2023. e-Pub 2023. PMID: 37326810.
- Holder AM, Wargo JA, Ross MI. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma. Ann Surg Oncol 30(12):7688. e-Pub 2023. PMID: 37597079.
- Soliman BG, Lim S, Schwartz MR, Krishnan K, Bernicker EH, Holder AM. Peritoneal recurrence of early-stage gastric cancer with associated endoscopic tattoo pigment two years after total gastrectomy and D2 lymphadenectomy. ACS Case Reviews:3(7): 92-95, 2022. e-Pub 2022.
- Rattani, A, Gaskins, J, McKenzie, G, Scharf, VK, Broman, KK, Pisu, M, Holder, AM, Dunlap, NE, Schwartz, DL, Yusuf, MB. Patterns of Care and Data Quality in a National Registry of Black and White Patients with Merkel Cell Carcinoma. Cancers 14(20), 2022. e-Pub 2022. PMID: 36291843.
- Podrat JL, Chegireddy V, Sheu T, Anton R, Satkunasivam R, Holder AM. Retroperitoneal fibrosis: a harbinger of metastatic gastric adenocarcinoma. ACS Case Reviews in Surgery 3(6):98-102, 2022. e-Pub 2022.
- von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder AM, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(7):815-833, 2022. e-Pub 2022. PMID: 35830886.
- Helmey S, Rose JB, Chen H, Holder AM. Ranking NIH Funding of Surgical Departments Based Upon a Modified Index. J Surg Res(270):335-340, 2022. e-Pub 2022. PMID: 34731731.
- Mehren V, M, Kane, J M, III, Riedel, R F, Sicklick, J K, Pollack, S M, Agulnik, M, Bui, M M, Carr-Ascher, J, Choy, E, Connelly, M, Dry, S, Ganjoo, K N, Gonzalez, R J, Holder AM, Homsi, J, Keedy, V, Kelly, C M, Kim, E, Liebner, D, McCarter, M, McGarry, S V, Mesko, N W, Meyer, C, Pappo, A S, Parkes, A M, Petersen, I A, Poppe, M, Schuetze, S, Shabason, J, Spraker, M B, Zimel, M, Bergman, M A, Sundar, H, Hang, L E. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network:20(11), 1204-1214, 2022. e-Pub 2022.
- Chen C, Schwartz MR, Holder AM. Diagnosis and Management of Vulvar Malignant Melanoma, An Uncommon and Aggressive Mucosal Melanoma. ACS Case Reviews in Surgery 3(4):38-41, 2022. e-Pub 2022.
- Schmults, C D, Blitzblau, R, Aasi, S Z, Alam, M, Andersen, J S, Baumann, B C, Bordeaux, J, Chen, P, Chin, R, Contreras, C M, DiMaio, D, Donigan, J M, Farma, J M, Ghosh, K, Grekin, R C, Harms, K, Ho, A L, Holder A, Lukens, J N, Medina, T, Nehal, K S, Nghiem, P, Park, S, Patel, T, Puzanov, I, Scott, J, Sekulic, A, Shaha, A R, Srivastava, D, Stebbins, W, Thomas, V, Xu, Y G, McCullough, B, Dwyer, M A, Nguyen, M Q. NCCN Guidelines® Insights: Squamous Cell Skin Cancer. Journal of the National Comprehensive Cancer Network:19(12), 1382-1394, 2022. e-Pub 2022. PMID: 34902824.
- Schmults, CD, Blitzblau, R, Aasi, SZ, Alam, M, Andersen, J, Baumann, BC, Bordeaux, JS, Chen, PL, Chin, RK, Contreras, CM, DiMaio, D, Donigan, JM, Farma, JM, Ghosh, K, Grekin, RC, Harms, KL, Ho, AL, Holder, AM, Lukens, JN, Medina, T, Nehal, KS, Nghiem, P, Park, S, Patel, T, Puzanov, I, Scott, J, Sekulic, A, Shaha, AR, Srivastava, D, Stebbins, WG, Thomas, V, Xu, YG, McCullough, B, Dwyer, M, Nguyen, MQ. Squamous Cell Skin Cancer, Version 1.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network 19(12):1382-1394, 2021. e-Pub 2021. PMID: 34902824.
- Court, KA, Yu, H, Chan, D, Blanco, E, Ziemys, A, Holder, AM. Gold Nanorod Hydrogel Film for Laser-Induced Hyperthermic Intraperitoneal Chemotherapy to Treat Peritoneal Malignancies. Advanced NanoBiomed Research 1(2), 2021. e-Pub 2021.
- Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder AM, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 19(4):364-376, 2021. e-Pub 2021. PMID: 33845460.
- Holder AM, Ziemys A. Lymphatic Transport Efficiency to Determine Metastatic Potential of Cutaneous Melanoma. Front Oncol 11(10):1607, 2020. e-Pub 2020.
- Ziemys A, Kim M, Menzies A, Wilmott JS, Long GV, Scolyer RA, Kwong L, Holder AM, Boland G. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Front Oncol:10:757, 2020. e-Pub 2020.
- Ziemys A, Yokoi K, Kai M, Liu YT, Kojic M, Simic V, Milosevic M, Holder AM, Ferrari M. Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance. J Control Release:291:99-105, 2018. e-Pub 2018.
- Mu C, Wu X, Wolfram J, Shen H, Zhang D, Mai J, Xia X, Holder AM, Liu X, Ferrari M. Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer. Clin Cancer Res 24(19):4900-4912, 2018. e-Pub 2018.
- Holder A, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 8(11):e0136851, 2016. e-Pub 2016. PMID: 26953790.
- McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 10(9):e0136851, 2015. e-Pub 2015.
- Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget 6(23):19500-13, 2015. e-Pub 2015.
- Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 5(18):8544-57, 2014. e-Pub 2014.
- Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am 22(4):641-64, 2013. e-Pub 2013.
- Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 2013. e-Pub 2013.
- Wat MJ, Beck TF, Hernandez-Garcia A, Yu Z, Veenma D, Garcia M, Holder AM, Wat JJ, Chen Y, Mohila CA, Lally KP, Dickinson M, Tibboel D, de Klein A, Lee B, Scott DA. Mouse model reveals the role of SOX7 in the development of congenital diaphragmatic hernia associated with recurrent deletions of 8p23.1. Hum Mol Genet 21(18):4115-25, 2012. e-Pub 2012.
- Wat MJ, Veenma D, Hogue J, Holder AM, Yu Z, Wat J, Hanchard N, Shchelochkov O, Fernandes C, Johnson A, Lally KP, Slavotinek A, Danhaive O, Schaible T, Cheung SW, Rauen KA, Tonk VS, Tibboel D, de Klein A, Scott DA. Genomic alterations that contribute to the development of isolated and non-isolated congenital diaphragmatic hernia. J Med Genet 48(5):299-307, 2011. e-Pub 2011.
- Wat MJ, Shchelochkov OA, Holder AM, Breman AM, Dagli A, Bacino C, Scaglia F, Zori RT, Cheung SW, Scott DA, S-HL K. Chromosome 8p23.1 deletions as a cause of complex congenital heart defects and diaphragmatic hernia. Am J Med Genet A 149A(8):1661-77, 2009. e-Pub 2009.
- Holder AM, Graham BH, Lee B, Scott DA. Fine-Lubinsky syndrome: sibling pair suggests possible autosomal recessive inheritance. Am J Med Genet A: Case Reports 143A(21):2576-80, 2007. e-Pub 2007. PMID: 17394214.
- Scott DA, Klaassens M, Holder AM, Lally KP, Fernandes CJ, Galjaard RJ, Tibboel D, de Klein A, Lee B. Genome-wide oligonucleotide-based array comparative genome hybridization analysis of non-isolated congenital diaphragmatic hernia. Hum Mol Genet 16:424-30, 2007. e-Pub 2007. PMID: 17210672.
- Hovsepian DM, Mandava A, Pilgram TK, Holder AM, Wong V, Chan P, Patel T. Comparison of adjunctive use of rofecoxib versus ibuprofen in the management of postoperative pain after uterine artery embolization. J Vasc Interv Radiol 17(4):665-70, 2006. e-Pub 2006. PMID: 16614150.
Review Articles
- Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, Boland GM. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer 24(7):498-512, 2024. e-Pub 2024. PMID: 38867074.
- Haddad A, Holder AM. Microbiome and Immunotherapy for Melanoma: Are We Ready for Clinical Application?. Hematol Oncol Clin North Am 38(5):1061-1070, 2024. e-Pub 2024. PMID: 38908958.
- Suresh R, Ziemys A, Holder AM. Dissecting the Lymphatic System to Predict Melanoma Metastasis. Frontiers in Oncology. Front Oncol: Skin Cancer:10:576190, 2020. e-Pub 2020.
- Holder AM, Klaassens M, Tibboel D, de Klein A, Lee B, Scott DA. Genetic factors in congenital diaphragmatic hernia. Am J Hum Genet 80(5):825-845, 2007. e-Pub 2007.
Book Chapters
- Holder AM, Varadhachary G. In: Cancer of Unknown Primary Site” in The MD Anderson Surgical Oncology Handbook, 613-626, 2019.
- Holder AM, Mutch M. In: Anorectal Disease in The Washington University Manual of Surgery, 266-300, 2015.
- Holder AM, Meric-Bernstam F. In: Toward Personalized Therapy for Cancer in Targeted Therapy in Translational Cancer Research, 3-13, 2015.
- Holder AM, Hotchkiss RS. In: Fluids, Electrolytes, and Acid-Base Disorders in The Washington University Manual of Surgery, 100-123, 2011.
Patents
- ChemothermixTM. Patent Number: US Serial Number: 88306599.
- Gold Nanoparticle-Containing Hydrogel Films and Chemotherapeutic Methods for Using the Same. Patent Number: US Serial Number: 62/803,776.
Patient Reviews
CV information above last modified July 22, 2026